Cytochrome P450-mediated Metabolism of Estrogens and Its Regulation in Human

Estrogens are eliminated from the body by metabolic conversion to estrogenically inactive metabolites that are excreted in the urine and/or feces. The first step in the metabolism of estrogens is the hydroxylation catalyzed by cytochrome P450 (CYP) enzymes. Since most CYP isoforms are abundantly expressed in liver, the metabolism of estrogens mainly occurs in the liver. A major metabolite of estradiol, 2-hydroxyestradiol, is mainly catalyzed by CYP1A2 and CYP3A4 in liver, and by CYP1A1 in extrahepatic tissues. However, CYP1B1 which is highly expressed in estrogen target tissues including mammary, ovary, and uterus, specifically catalyzes the 4-hydroxylation of estradiol. Since 4-hydroxyestradiol generates free radicals from the reductive-oxidative cycling with the corresponding semiquinone and quinone forms, which cause cellular damage, the specific and local formation of 4-hydroxyestradiol is important for breast and endometrial carcinogenesis. Changes in the expression level of estrogen-metabolizing CYP isoforms not only alter the intensity of the action of estrogen but may also alter the profile of its physiological effect in liver and target tissues. Generally, many CYP isoforms are induced by the substrates themselves, resulting in enhanced metabolism and elimination from the body. Of particular interest is a novel finding that human CYP1B1 is regulated by estradiol via the estrogen receptor. This fact suggests that the regulation of CYP enzymes involved in estrogen metabolism by estrogen itself would be physiologically significant for the homeostasis of estrogens at local organs. In this mini-review, we discuss the CYP-mediated metabolism of estrogens and the regulation of the estrogen-metabolizing CYP enzymes in relation to the risk of cancer.

[1]  P. Chambon,et al.  Functional domains of the human estrogen receptor , 1987, Cell.

[2]  J. Seegers,et al.  The cytotoxic effects of estradiol-17 beta, catecholestradiols and methoxyestradiols on dividing MCF-7 and HeLa cells. , 1989, Journal of steroid biochemistry.

[3]  R. Evans,et al.  The steroid and thyroid hormone receptor superfamily. , 1988, Science.

[4]  A. Conney,et al.  Functional role of estrogen metabolism in target cells: review and perspectives. , 1998, Carcinogenesis.

[5]  P. Ball,et al.  Formation of 2- and 4-Hydroxyestrogens by Brain, Pituitary, and Liver of the Human Fetus* , 1978 .

[6]  F. Bresciani,et al.  Estrogen stimulates transcription of c-jun protooncogene. , 1990, Molecular endocrinology.

[7]  Joseph,et al.  Cloning and Expression of Human Liver UDP-glucuronosyltransferase in COS- 1 Cells , 2001 .

[8]  P. Siiteri.  Adipose tissue as a source of hormones. , 1987, The American journal of clinical nutrition.

[9]  Peter Neuhaus,et al.  Sex is a major determinant of CYP3A4 expression in human liver , 2003, Hepatology.

[10]  J. Heidel,et al.  Increased catechol estrogen metabolism as a risk factor for nonfamilial breast cancer , 1992, Cancer.

[11]  L. Quattrochi,et al.  Interaction of upstream stimulatory factor proteins with an E-box located within the human CYP1A2 5'-flanking gene contributes to basal transcriptional gene activation. , 2003, Biochemical pharmacology.

[12]  K. Korzekwa,et al.  Estradiol metabolism by complementary deoxyribonucleic acid-expressed human cytochrome P450s. , 1990, Endocrinology.

[13]  H. McLeod,et al.  CYP3A4 and VDR gene polymorphisms and the risk of prostate cancer in men with benign prostate hyperplasia , 2003, British Journal of Cancer.

[14]  Michael S. Pepper,et al.  The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth , 1994, Nature.

[15]  M. Pike,et al.  Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. , 1993, Epidemiologic reviews.

[16]  R. Guzman,et al.  Hormones and mammary carcinogenesis in mice, rats, and humans: a unifying hypothesis. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[17]  F. Guengerich.  Oxidation of 17 alpha-ethynylestradiol by human liver cytochrome P-450. , 1988, Molecular pharmacology.

[18]  A. Børresen-Dale,et al.  Molecular epidemiology of breast cancer: genetic variation in steroid hormone metabolism. , 2000, Mutation research.

[19]  L. Wu,et al.  Organization and function of a dioxin-responsive enhancer. , 1990, The Journal of biological chemistry.

[20]  K. Anderson,et al.  Abnormal oxidative metabolism of estradiol in women with breast cancer. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[21]  M. Nakajima,et al.  Critical enhancer region to which AhR/ARNT and Sp1 bind in the human CYP1B1 gene. , 2003, Journal of biochemistry.

[22]  D W Nebert,et al.  P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. , 1996, Pharmacogenetics.

[23]  C. E. Hudson,et al.  Steroid hormones modulate expression of cytochrome P450 enzymes in male hamster reproductive tract and leiomyosarcomas. , 2001, Carcinogenesis.

[24]  J. Liehr.  Is Estradiol a Genotoxic Mutagenic Carcinogen ? * , 2000 .

[25]  M. Pike,et al.  Toward the primary prevention of cancer. , 1991, Science.

[26]  S. Kliewer,et al.  Regulation of cyp3a gene transcription by the pregnane x receptor. , 2002, Annual review of pharmacology and toxicology.

[27]  T. Gasiewicz,et al.  The human estrogen receptor structural gene contains a DNA sequence that binds activated mouse and human Ah receptors: a possible mechanism of estrogen receptor regulation by 2,3,7,8-tetrachlorodibenzo-p-dioxin. , 1993, Biochemical and biophysical research communications.

[28]  R. Weinshilboum,et al.  Sulfation of estrone and 17 beta-estradiol in human liver. Catalysis by thermostable phenol sulfotransferase and by dehydroepiandrosterone sulfotransferase. , 1992, Drug metabolism and disposition: the biological fate of chemicals.

[29]  C. Bradfield,et al.  Ah receptor signaling pathways. , 1996, Annual review of cell and developmental biology.

[30]  O. Hankinson.  The aryl hydrocarbon receptor complex. , 1995, Annual review of pharmacology and toxicology.

[31]  C. Junien,et al.  Candidate genetic modifiers of individual susceptibility to renal cell carcinoma: a study of polymorphic human xenobiotic-metabolizing enzymes. , 1999, Cancer research.

[32]  S. Kyo,et al.  Human CYP1B1 is regulated by estradiol via estrogen receptor. , 2004, Cancer research.

[33]  F. Behm,et al.  Genetic polymorphisms in CYP3A5, CYP3A4 and NQO1 in children who developed therapy-related myeloid malignancies. , 2002, Pharmacogenetics.

[34]  A Poland,et al.  2,3,7,8-tetrachlorodibenzo-p-dioxin and related halogenated aromatic hydrocarbons: examination of the mechanism of toxicity. , 1982, Annual review of pharmacology and toxicology.

[35]  D. Roy,et al.  Elevated 4-hydroxylation of estradiol by hamster kidney microsomes: a potential pathway of metabolic activation of estrogens. , 1992, Endocrinology.

[36]  A. Conney,et al.  Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. , 2003, Endocrinology.

[37]  R. Santen,et al.  In situ estrogen production via the estrone sulfatase pathway in breast tumors: relative importance versus the aromatase pathway. , 1984, The Journal of clinical endocrinology and metabolism.

[38]  K. Korzekwa,et al.  Role of human hepatic cytochrome P450 1A2 and 3A4 in the metabolic activation of estrone. , 1997, Carcinogenesis.

[39]  H. Adlercreutz,et al.  Diet and urinary estrogen profile in premenopausal omnivorous and vegetarian women and in premenopausal women with breast cancer. , 1989, Journal of steroid biochemistry.

[40]  G. G. Stokes.  "J." , 1890, The New Yale Book of Quotations.

[41]  F. Gonzalez,et al.  Role of the aryl hydrocarbon receptor and Cyp1b1 in the antiestrogenic activity of 2,3,7,8-tetrachlorodibenzo-p-dioxin , 2004, Archives of Toxicology.

[42]  J. Frasor,et al.  Selective Estrogen Receptor Modulators , 2004, Cancer Research.

[43]  R. D'Amato,et al.  Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. , 1997, Cancer research.

[44]  N. Roodi,et al.  Cytochrome P450 1B1 (CYP1B1) pharmacogenetics: association of polymorphisms with functional differences in estrogen hydroxylation activity. , 2000, Cancer research.

[45]  N. Roodi,et al.  Association of cytochrome P450 1B1 (CYP1B1) polymorphism with steroid receptor status in breast cancer. , 1998, Cancer research.

[46]  H. Yamazaki,et al.  Activation of chemically diverse procarcinogens by human cytochrome P-450 1B1. , 1996, Cancer research.

[47]  C. Martucci,et al.  P450 enzymes of estrogen metabolism. , 1993, Pharmacology & therapeutics.

[48]  Y. Shiotsu,et al.  Systemic distribution of steroid sulfatase and estrogen sulfotransferase in human adult and fetal tissues. , 2002, The Journal of clinical endocrinology and metabolism.

[49]  Paavo Honkakoski,et al.  The Repressed Nuclear Receptor CAR Responds to Phenobarbital in Activating the Human CYP2B6 Gene* , 1999, The Journal of Biological Chemistry.

[50]  M. Esteller,et al.  Endometrial carcinoma in tamoxifen-treated breast cancer patient: clinicopathological, immunohistochemical, and genetic analysis. , 1999, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[51]  J. Liehr,et al.  4-Hydroxylation of estrogens as marker of human mammary tumors. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[52]  G. Emons,et al.  Metabolism of exogenous 4- and 2-hydroxyestradiol in the human male. , 1986, Journal of steroid biochemistry.

[53]  Takashi Suzuki,et al.  17-Beta-Hydroxysteroid Dehydrogenase in Human Breast and Endometrial Carcinoma , 2000, Oncology.

[54]  J. Ritter,et al.  Cloning and expression of human liver UDP-glucuronosyltransferase in COS-1 cells. 3,4-catechol estrogens and estriol as primary substrates. , 1990, The Journal of biological chemistry.

[55]  A. Conney,et al.  Characterization of the NADPH-dependent metabolism of 17beta-estradiol to multiple metabolites by human liver microsomes and selectively expressed human cytochrome P450 3A4 and 3A5. , 2001, The Journal of pharmacology and experimental therapeutics.

[56]  S. Safe,et al.  Crosstalk between estrogen receptor α and the aryl hydrocarbon receptor in breast cancer cells involves unidirectional activation of proteasomes , 2000, FEBS letters.

[57]  J. Li,et al.  Carcinogenic activities of various steroidal and nonsteroidal estrogens in the hamster kidney: relation to hormonal activity and cell proliferation. , 1995, Cancer research.

[58]  J A McKay,et al.  Tumor-specific expression of cytochrome P450 CYP1B1. , 1997, Cancer research.

[59]  D. Lewis,et al.  Homology modelling of the nuclear receptors: human oestrogen receptorbeta (hERbeta), the human pregnane-X-receptor (PXR), the Ah receptor (AhR) and the constitutive androstane receptor (CAR) ligand binding domains from the human oestrogen receptor alpha (hERalpha) crystal structure, and the human pe , 2003, Journal of Steroid Biochemistry and Molecular Biology.

[60]  S. Anttila,et al.  Expression of CYP1B1 in human adult and fetal tissues and differential inducibility of CYP1B1 and CYP1A1 by Ah receptor ligands in human placenta and cultured cells. , 1997, Carcinogenesis.

[61]  P. Siiteri,et al.  Effect of obesity on conversion of plasma androstenedione to estrone in postmenopausal women with and without endometrial cancer. , 1978, American journal of obstetrics and gynecology.

[62]  L. Nutter,et al.  Characterization of DNA damage induced by 3,4-estrone-o-quinone in human cells. , 1991, The Journal of biological chemistry.

[63]  E. Taioli,et al.  A CYP1A1 restriction fragment length polymorphism is associated with breast cancer in African-American women. , 1995, Cancer research.

[64]  A. Daly,et al.  Cytochrome P450 CYP1B1 and catechol O-methyltransferase (COMT) genetic polymorphisms and breast cancer susceptibility in a Turkish population , 2002, Archives of Toxicology.

[65]  P. Siiteri,et al.  Source of estrogen production in postmenopausal women. , 1973, The Journal of clinical endocrinology and metabolism.

[66]  J. Liehr,et al.  4-Hydroxylation of estradiol by human uterine myometrium and myoma microsomes: implications for the mechanism of uterine tumorigenesis. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[67]  D. Lin,et al.  Development of an antipeptide antibody that binds to the C-terminal region of human CYP1B1. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[68]  L. Nutter,et al.  An o-quinone form of estrogen produces free radicals in human breast cancer cells: correlation with DNA damage. , 1994, Chemical research in toxicology.

[69]  C. Eap,et al.  Identification of a novel splice-site mutation in the CYP1A2 gene. , 2003, British journal of clinical pharmacology.

[70]  P. Ball,et al.  Catecholoestrogens (2-and 4-hydroxyoestrogens): chemistry, biogenesis, metabolism, occurrence and physiological significance. , 1980, Acta endocrinologica. Supplementum.

[71]  G. Giles,et al.  The CYP3A4*1B polymorphism has no functional significance and is not associated with risk of breast or ovarian cancer. , 2002, Pharmacogenetics.

[72]  J. Pascussi,et al.  The expression of CYP2B6, CYP2C9 and CYP3A4 genes: a tangle of networks of nuclear and steroid receptors. , 2003, Biochimica et biophysica acta.

[73]  J. Whitlock,et al.  Induction of cytochrome P4501A1. , 1999, Annual review of pharmacology and toxicology.

[74]  村田 万里子.  Cytochrome P4501A1 and glutathione S-transferase M1 genotypes as risk factors for prostate cancer in Japan , 2000 .

[75]  O. Gotoh,et al.  Xenobiotic responsive element in the 5'-upstream region of the human P-450c gene. , 1991, Journal of biochemistry.

[76]  N. Walker,et al.  17 beta-estradiol hydroxylation catalyzed by human cytochrome P450 1B1. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[77]  Kazuo Komamura,et al.  Six Novel Nonsynonymous CYP1A2 Gene Polymorphisms: Catalytic Activities of the Naturally Occurring Variant Enzymes , 2004, Journal of Pharmacology and Experimental Therapeutics.

[78]  A. Conney,et al.  NADPH-dependent metabolism of estrone by human liver microsomes. , 2002, The Journal of pharmacology and experimental therapeutics.

[79]  J. Liehr,et al.  Induction of uterine adenocarcinoma in CD-1 mice by catechol estrogens. , 2000, Cancer research.

[80]  R. Tukey,et al.  The human cytochrome Cyp1A2 gene contains regulatory elements responsive to 3-methylcholanthrene. , 1989, Molecular pharmacology.

[81]  S. Safe,et al.  Comparative toxicology and mechanism of action of polychlorinated dibenzo-p-dioxins and dibenzofurans. , 1986, Annual review of pharmacology and toxicology.

[82]  Ann Daly,et al.  Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression , 2001, Nature Genetics.

[83]  E. T. Williams,et al.  Estrogen Regulation of the Cytochrome P450 3A Subfamily in Humans , 2004, Journal of Pharmacology and Experimental Therapeutics.

[84]  P. Ball,et al.  Formation of 2− and 4‐Hydroxyestrogens by Brain, Pituitary and Liver of the Human Fetus , 1979, The Journal of clinical endocrinology and metabolism.

[85]  R. Dahiya,et al.  CYP1B1 gene polymorphisms have higher risk for endometrial cancer, and positive correlations with estrogen receptor alpha and estrogen receptor beta expressions. , 2003, Cancer research.

[86]  E. Bresnick,et al.  Identification of positive and negative regulatory elements of the human cytochrome P4501A2 (CYP1A2) gene. , 1997, Archives of biochemistry and biophysics.

[87]  L. Kolonel,et al.  Case-control study of ovarian cancer and polymorphisms in genes involved in catecholestrogen formation and metabolism. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[88]  J. Freudenheim,et al.  Cytochrome P4501A1 and glutathione S-transferase (M1) genetic polymorphisms and postmenopausal breast cancer risk. , 1995, Cancer research.

[89]  L. Marchand,et al.  CYP1A1, GSTM1, and GSTT1 polymorphisms and the risk of cervical squamous intraepithelial lesions in a multiethnic population. , 2001, Gynecologic oncology.

[90]  I. Kharat,et al.  Antiestrogenic Effects of 2,3,7,8-Tetrachlorodibenzo-p-dioxin Are Mediated by Direct Transcriptional Interference with the Liganded Estrogen Receptor , 1996, The Journal of Biological Chemistry.

[91]  B. Henderson,et al.  Estrogens and breast cancer. , 1996, Carcinogenesis.